Showing 1 - 10 of 99
Standards, common platforms allowing products to work together, are ubiquitous in our economy. But imagine that a company:(1) has a patent needed to use a standard, (2) promises to license the patent on reasonable terms, and then (3) says it was just kidding as it seeks to block the product or...
Persistent link: https://www.econbiz.de/10012831378
As CEO of Turing Pharmaceuticals, Martin Shkreli made worldwide headlines by obtaining marketing rights to pyrimethamine (Daraprim) and quickly increasing the price 5000 percent, from $13.50 to $750 per pill. In addition to increasing price, Turing initiated another less widely appreciated move...
Persistent link: https://www.econbiz.de/10012970155
Drug prices are in the news. “Pharma Bro” Martin Shkreli increased the price of Daraprim, a treatment for fatal parasitic infections, by 5000%. Mylan found itself on the hot seat for raising the price of the anaphylaxis-treating EpiPen 15 times in 7 years, resulting in a 400% increase to...
Persistent link: https://www.econbiz.de/10012978113
Rising drug prices are in the news. By increasing price, drug companies have placed vital, even life-saving, medicines out of the reach of consumers. In a recent development, brand firms have prevented generics even from entering the market. The ruse for this strategy involves risk-management...
Persistent link: https://www.econbiz.de/10012955066
Big Tech is in the news. At the center of our political and economic dialogue is the effect that Amazon, Apple, Facebook, and Google have on our lives and what, if anything, governments should do about it. In this short piece, I explain how Big Tech has come under scrutiny, the antitrust...
Persistent link: https://www.econbiz.de/10012834909
Persistent link: https://www.econbiz.de/10012849905
Pharmaceutical antitrust law is hard. When drug companies delay generic entry, is that beneficial “life-cycle management”? Or is it unjustified anti-competitive behavior? The question arises in multiple settings, including patent settlements by which brand firms pay generics to delay...
Persistent link: https://www.econbiz.de/10014107207
Persistent link: https://www.econbiz.de/10014110600
Causation is one of the most underexplored areas in antitrust law. What must a plaintiff show to connect a defendant’s conduct with anticompetitive effects? Several tests are possible, including “but for” causation, proximate cause, sole causation, reasonable connection, and increased...
Persistent link: https://www.econbiz.de/10014176575